IOVANCE BIOTHERAPEUTICS, INC. (IOVA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
IOVA currently has 334M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 32.83% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2025 |
10-Q filing | 333.9M shares outstanding |
330M | 0 |
| Feb 27, 2025 |
10-K filing | 256.1M shares outstanding |
260M | 0 |
| Nov 07, 2024 |
10-Q filing | 304.6M shares outstanding |
300M | 0 |
| Aug 08, 2024 |
10-Q filing | 297.3M shares outstanding |
300M | 0 |
| May 09, 2024 |
10-Q filing | 266.2M shares outstanding |
270M | 0 |
| Feb 28, 2024 |
10-K filing | 256.1M shares outstanding |
260M | 0 |
| Feb 22, 2024 |
8-K filing: Iovance Biotherapeutics, Inc. closed the sale of 23,014,000 shares of its common stock at $9.15 per share in an offering, resulting in net proceeds of approximately $197.1 million. ($197.1M proceeds) |
250M | 0 |
| Feb 20, 2024 |
8-K filing: Iovance Biotherapeutics, Inc. entered into an underwriting agreement to issue and sell up to 23,014,000 shares of common stock at $9.15 per share, with net proceeds estimated at approximately $197.1 million, intending to use the proceeds for commercial launch, clinical programs, pipeline development, and general corporate purposes. The offering is expected to close on February 22, 2024. |
250M | 0 |
| Nov 07, 2023 |
10-Q filing | 245.8M shares outstanding |
250M | 0 |
| Aug 08, 2023 |
10-Q filing | 224.5M shares outstanding |
220M | 0 |
| Jul 13, 2023 |
8-K filing: Iovance Biotherapeutics, Inc. closed the sale of 23,000,000 shares of its common stock at a public offering price of $7.50 per share, resulting in net proceeds of approximately $161.4 million. ($161.4M proceeds) |
210M | 0 |
| Jul 11, 2023 |
8-K filing: Iovance Biotherapeutics, Inc. entered into an underwriting agreement to issue and sell up to 23,000,000 shares of common stock at a public offering price of $7.50 per share, with the offering expected to close on July 13, 2023. ($140.2M proceeds) |
210M | 0 |
| May 10, 2023 |
10-Q filing | 213.7M shares outstanding |
210M | 0 |
| Feb 28, 2023 |
10-K filing | 187.8M shares outstanding |
190M | 0 |
| Nov 03, 2022 |
10-Q filing | 157.8M shares outstanding |
160M | 0 |
| Aug 04, 2022 |
10-Q filing | 157.3M shares outstanding |
160M | 0 |
| May 05, 2022 |
10-Q filing | 157.2M shares outstanding |
160M | 0 |
| Feb 24, 2022 |
10-K filing | 157.0M shares outstanding |
160M | 0 |
| Nov 04, 2021 |
10-Q filing | 156.7M shares outstanding |
160M | 0 |
| Aug 05, 2021 |
10-Q filing | 146.9M shares outstanding |
150M | 0 |
| May 06, 2021 |
10-Q filing | 146.9M shares outstanding |
150M | 0 |
| Feb 25, 2021 |
10-K filing | 126.4M shares outstanding |
130M | 0 |
| Nov 05, 2020 |
10-Q filing | 126.4M shares outstanding |
130M | 0 |
| Aug 06, 2020 |
10-Q filing | 146.4M shares outstanding |
150M | 0 |
| Jun 02, 2020 |
8-K filing: Iovance Biotherapeutics, Inc. closed the sale of 19,475,806 shares of its common stock at a public offering price of $31.00 per share, resulting in net proceeds of approximately $567.0 million. ($567.0M proceeds) |
130M | 0 |
| May 29, 2020 |
8-K filing: Iovance Biotherapeutics, Inc. entered into an underwriting agreement for a public offering of 16,935,484 shares of common stock at $31.00 per share, with the underwriters purchasing the shares at $29.14 per share, and granted the underwriters an option to purchase up to 2,540,322 additional shares. ($493.0M proceeds) |
130M | 0 |
| May 05, 2020 |
10-Q filing | 126.8M shares outstanding |
130M | 0 |
| Feb 25, 2020 |
10-K filing | 123.4M shares outstanding |
120M | 0 |